Please login to the form below

Not currently logged in
Email:
Password:

Pfizer scraps RA drug

Pfizer has decided to scrap development of TRU-015 for the treatment of rheumatoid arthritis

Pfizer has decided to scrap development of a drug for a very large market – rheumatoid arthritis (RA). Seattle-based Trubion Pharmaceuticals, which has a collaboration in RA with the company, said that Pfizer has terminated development of TRU-015, a protein therapeutic product.

The decision is based on a phase IIb study which did not meet its primary endpoint of a 20 per cent reduction on an American College of Rheumatology disease scoring index compared to placebo.

Trubion noted that Pfizer intends to continue development of another RA product that is part of the collaboration, SBI-087. That drug is currently in a phase II study.

15th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics